Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The proteasome: structure, function, and role in the cell.

Julian Adams1

  • 1Millennium Pharmaceuticals, Inc., Cambridge, MA 02139, USA. jadams@mpi.com

Cancer Treatment Reviews
|May 10, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A multifaceted kinase axis regulates plant organ abscission through conserved signaling mechanisms.

Current biology : CB·2024
Same author

Candidate genes affecting stomatal density in rice (Oryza sativa L.) identified by genome-wide association.

Plant science : an international journal of experimental plant biology·2023
Same author

Targeting CDK9 for treatment of colorectal cancer.

Molecular oncology·2019
Same author

Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer.

Proceedings of the National Academy of Sciences of the United States of America·2018
Same author

CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia.

Investigational new drugs·2018
Same author

COEVOLUTION IN BACTERIAL-PLASMID POPULATIONS.

Evolution; international journal of organic evolution·2017
Same journal

Neoadjuvant and adjuvant therapy in uveal melanoma: toward systemic control of a systemic disease.

Cancer treatment reviews·2026
Same journal

Antiangiogenic therapies in gastric cancer: future directions for 2026 and beyond: an UNICANCER gastrointestinal group (UCGI) perspective.

Cancer treatment reviews·2026
Same journal

Treatment of breast cancer brain metastases in the era of novel drugs.

Cancer treatment reviews·2026
Same journal

Standardization of objectives and response criteria for neoadjuvant immunotherapy in resectable squamous cell carcinoma of the head and neck.

Cancer treatment reviews·2026
Same journal

Precision targeting of CLDN18.2: A new therapeutic paradigm for gastric cancer.

Cancer treatment reviews·2026
Same journal

Beyond body surface area: CT-derived body composition as a predictor of chemotherapy toxicity and survival in pancreatic ductal adenocarcinoma: a systematic review.

Cancer treatment reviews·2026
See all related articles

The proteasome regulates cell cycle and apoptosis, making it a cancer therapy target. Bortezomib (VELCADE) inhibits the proteasome, showing antitumor activity in studies and advancing to clinical trials.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • The proteasome is a crucial enzyme complex regulating proteins involved in cell-cycle progression and apoptosis.
  • Protein degradation is initiated by ubiquitination, leading to polyubiquitin chain attachment for proteasome recognition.
  • The proteasome's 19S cap binds ubiquitinated proteins, denatures them, and channels them to the proteolytic core for degradation.

Purpose of the Study:

  • To investigate the role of proteasome inhibition as an anticancer therapy.
  • To evaluate the efficacy of bortezomib (VELCADE) in preclinical and clinical settings.

Main Methods:

  • Inhibition of proteasome activity using bortezomib.
  • In vitro and in vivo animal studies to assess antitumor effects.

Related Experiment Videos

  • Clinical trials for various tumor types, including multiple myeloma.

    • Main Results:

    • Proteasome inhibition leads to cell-cycle arrest and apoptosis.
    • Bortezomib demonstrated significant antitumor activity across multiple tumor types, both as a monotherapy and in combination regimens.
    • Bortezomib is currently in Phase III trials for myeloma and under investigation for other cancers.

    Conclusions:

    • The proteasome is a validated therapeutic target for anticancer drug development.
    • Bortezomib represents a promising agent for cancer treatment, with ongoing clinical evaluation supporting its therapeutic potential.